Drugs / GS1-144
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07534176 | May → Oct 2026 expected | — | Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07491289 | Apr 2026 → Jan 2027 expected | — | Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07537231 | Apr 2026 overdue | — | Changchun GeneScience Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06983925 | Apr → Jul 2025 | — | Changchun GeneScience Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06204250 | Feb → Dec 2024 | — | Changchun GeneScience Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06385158 | Jan 2024 | — | Changchun GeneScience Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT06726850 | Oct 2024 → Apr 2025 | vascular disorder | Changchun GeneScience Pharmaceutical Co., Ltd. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-04-29 | Changchun GeneScience Pharmaceutical Co., Ltd. | Results GenSci’s NK3R Antagonist for VMS Phase II Study Results Published in Menopause genscigroup.com ↗
The trial met its predefined co-primary endpoints, demonstrated favorable safety and tolerability, and no liver safety risks were observed. |
| 2025-10-24 | Changchun GeneScience Pharmaceutical Co., Ltd. | Results GenSci Announces Positive Phase II Results for GS1-144 Tablets in Chinese Postmenopausal Women with Moderate-to-Severe VMS genscigroup.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-29 | Changchun GeneScience Pharmaceutical Co., Ltd. | GenSci’s NK3R Antagonist for VMS Phase II Study Results Published in Menopause genscigroup.com ↗ |
| 2025-10-24 | Changchun GeneScience Pharmaceutical Co., Ltd. | GenSci Announces Positive Phase II Results for GS1-144 Tablets in Chinese Postmenopausal Women with Moderate-to-Severe VMS genscigroup.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GS1-144 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06204250 ↗ |
| Action | Inhibit | “GS1-144 tablet is an NK3R antagonist.” NCT06385158 ↗ |
| Route | Oral | “Oral tablets.” NCT06204250 ↗ |